Search for content, post, videos

Category

Business

0 COMMENT
37 Views
Aarhus hospital purchases system from Nexstim

Medtech company Nexstim announces that  Aarhus University Hospital, Denmark has recently purchased a Navigated Brain Stimulation (NBS) System. The NBS System at Aarhus University Hospital will be used for diagnostic brain mapping for the treatment of brain tumours and other neurologic related disorders. The neurosurgeons at Aarhus University Hospital Dr.…

0 COMMENT
35 Views
Moberg Pharma extends retail presence

Moberg Pharma expands retail presence for a second Dermoplast product in 7 500 CVS stores and 3 500 Walmart stores. Dermoplast was acquired from Prestige Brands, Inc. in December 2016, contributing to sales and profitability as of January 2017. There are two products under the Dermoplast brand and the additional distribution…

rd-astrazeneca-cambridge
0 COMMENT
46 Views
AstraZeneca marks a key milestone

AstraZeneca has made a successful move to Cambridge, UK, with the ‘topping out’ of its new strategic R&D centre and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC). The company, including its biologics research and development arm, MedImmune, already has 2 000 employees actively engaged in…

Recipharm-Research-Triangle-Park
0 COMMENT
62 Views
Recipharm opens new GMP suite

Recipharm has opened a newly built GMP suite for clinical trial material (CTM) manufacture at its facility in Research Triangle Park, North Carolina, USA. The suite, which represents a $750k investment, is intended to produce CTM for clinical studies up to Phase II for non-sterile dosage forms, including metered dose…

sean-bohen
0 COMMENT
11 Views
Tagrisso receives full approval in the EU

AstraZeneca announces that the European Commission (EC) has granted full marketing authorisation for Tagrisso (osimertinib) 40mg and 80mg once-daily tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). The full approval for Tagrisso is based on…

björn-sjöstrand-agreement
0 COMMENT
144 Views
Scandinavian Biopharma in agreement with Flynn Pharma

Scandinavian Biopharma has entered into an agreement with Flynn Pharma for the viper antivenom ViperaTAb. Under the agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany. “We are very pleased to strengthen our portfolio with an…

magnus-groth-sca
0 COMMENT
146 Views
SCA becomes two listed companies

At the Annual General Meeting of SCA last week, the company’s shareholders voted in favor of the Board of Director’s proposal to split the Group into two listed companies. Essity One of these will continue to operate as SCA, a forest products company that will include the forest products operations…

medfiles
0 COMMENT
179 Views
New international owner of Medfiles Ltd from Japan

On the 21st of March 2017, WDB Holdings Co., Ltd, a listed Japanese Contract Research Organisation, bought Medfiles Ltd (100 % of the shares). Medfiles Group has been operating in Finland for over 30 years and 20 years in the Baltic countries. In the CRO business, Medfiles sells services in product development,…

richard-godfrey-bergenbio
0 COMMENT
97 Views
BerGenBio announces the terms of its IPO

Further to the announcement on 8 March 2017 regarding the intention to list the shares of BerGenBio ASA on Oslo Børs and carry out an Initial Public Offering, BerGenBio announces the terms of the IPO. Subject to approval of the listing application and the successful completion of the IPO, the…

sean-bohen
0 COMMENT
186 Views
AstraZeneca’s Tagrisso approved in China

The China Food and Drug Administration has granted marketing authorisation for Tagrisso, 40 mg and 80mg once-daily oral tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer whose disease has progressed on or after EGFR tyrosine kinase inhibitor…

karolinska-institutet-science-park
0 COMMENT
127 Views
Aprea enters research collaboration

Aprea Therapeutics announces a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumor suppressor protein p53 by APR-246. The goal of the collaboration is to evaluate and characterize preclinical efficacy of APR-246 in combination with multiple other anti-cancer agents and across multiple tumor types.…

0 COMMENT
146 Views
Targovax moves share listing to Oslo Børs

Targovax announces that its shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. The company was previously listed on Oslo Axess, a regulated and licensed market under the auspices of the Oslo Stock Exchange. “This move marks another exciting step for Targovax. Being part of…

recipharm
0 COMMENT
185 Views
Recipharm manufactures to the Japanese market

Recipharm has entered into a long term agreement with Sato Pharmaceutical for the commercial manufacture and delivery of Emla Patch to Japan. Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato. Recipharm’s facility in Karlskoga, Sweden will…

mark_mallon
0 COMMENT
61 Views
AstraZeneca & Circassia enter strategic collaboration

AstraZeneca has entered a strategic collaboration with Circassia Pharmaceuticals for the development and commercialisation of Tudorza and Duaklir in the US. Tudorza and Duaklir are inhaled respiratory medicines for the treatment of chronic obstructive pulmonary disease (COPD). Tudorza was approved and launched in the US in 2012. Duaklir is expected…